Pricing And Reimbursement Reforms In Spain – A Systematic Analysis Of National Pricing Decisions By The CIPM

October 18, 2018 Danielle Twigg

Following marketing authorization in Spain, new medicines are assessed by the Inter-Ministerial Pricing Commission for Pharmaceuticals (CIPM), which provides reimbursement recommendations with a maximum ex-factory price. For innovative products, pricing is based on international reference pricing, with additional factors including unmet need and budget impact also playing a role. However, this price setting process can be very time-consuming (12-18 months), involving lengthy negotiations. In September 2017, major reforms were announced that included companies only being allowed to submit single price proposals to the CIPM to shorten this process. Since November 2017, CIPM recommendations have been published on a monthly basis. This research aims to systematically analyze all CIPM recommendations to date.

Authors: Richard Macaulay and Raquel Fernandez Dacosta

To find out more about this poster you can register to download it here after the ISPOR event.

Previous Article
Spanish Therapeutic Positioning Reports: 6-Year Update – Increasing In Frequency But Not Relevance?
Spanish Therapeutic Positioning Reports: 6-Year Update – Increasing In Frequency But Not Relevance?

Next Article
Right To Breathe, Right To Choose?
Right To Breathe, Right To Choose?